[go: up one dir, main page]

AU2002225881A1 - Treatment of chronic fatigue syndrome and fibromyalgia syndrome - Google Patents

Treatment of chronic fatigue syndrome and fibromyalgia syndrome

Info

Publication number
AU2002225881A1
AU2002225881A1 AU2002225881A AU2588102A AU2002225881A1 AU 2002225881 A1 AU2002225881 A1 AU 2002225881A1 AU 2002225881 A AU2002225881 A AU 2002225881A AU 2588102 A AU2588102 A AU 2588102A AU 2002225881 A1 AU2002225881 A1 AU 2002225881A1
Authority
AU
Australia
Prior art keywords
syndrome
treatment
chronic fatigue
fibromyalgia
fatigue syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225881A
Inventor
John L. Zenk
Ronald J. Zenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanetics Corp
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Publication of AU2002225881A1 publication Critical patent/AU2002225881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002225881A 2000-11-30 2001-10-31 Treatment of chronic fatigue syndrome and fibromyalgia syndrome Abandoned AU2002225881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25022700P 2000-11-30 2000-11-30
US60250227 2000-11-30
PCT/US2001/046241 WO2002043737A1 (en) 2000-11-30 2001-10-31 Treatment of chronic fatigue syndrome and fibromyalgia syndrome

Publications (1)

Publication Number Publication Date
AU2002225881A1 true AU2002225881A1 (en) 2002-06-11

Family

ID=22946861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225881A Abandoned AU2002225881A1 (en) 2000-11-30 2001-10-31 Treatment of chronic fatigue syndrome and fibromyalgia syndrome

Country Status (3)

Country Link
US (1) US7553829B2 (en)
AU (1) AU2002225881A1 (en)
WO (1) WO2002043737A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217357A1 (en) * 2003-01-13 2006-09-28 Humanetics Corporation Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
US7199116B2 (en) 2003-01-13 2007-04-03 Humanetics Corporation Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
WO2004062605A2 (en) * 2003-01-13 2004-07-29 Humanetics Corporation Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873699C (en) 1935-12-08 1953-04-16 Schering Ag Process for the preparation of oxygen-rich derivatives of unsaturated compounds of the androstane and pregnane series
US5461042A (en) 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5641768A (en) 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5641766A (en) 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5292730A (en) 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
EP0547151B1 (en) * 1990-08-29 2002-11-20 Humanetics Corporation Treatment process for promoting weight loss employing a substituted delta 5-androstene
US5585371A (en) 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
US5206008A (en) 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
WO1997004793A1 (en) 1995-08-02 1997-02-13 Ingram Teresa J Composition for administration to patients with chronic fatigue syndrome and acquired immune deficiency syndrome
US5885977A (en) 1997-01-15 1999-03-23 Humanetics Corporation Use of Δ5 androstenes in the treatment of HIV wasting syndrome
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
AU766908B2 (en) * 1997-11-19 2003-10-23 Humanetics Corporation Use of delta5-androstene-3beta-ol-7,17-dione in the treatment of arthritis
EP1032380A4 (en) 1997-11-19 2005-06-15 Humanetics Corp Use of delta 5-androstene-3 beta-ol-7,17-dione in the treatment of lupus erythematosus
US5935949A (en) * 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
US6153606A (en) 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof

Also Published As

Publication number Publication date
US7553829B2 (en) 2009-06-30
WO2002043737A1 (en) 2002-06-06
US20040038955A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU4171500A (en) Flupirtine in the treatment of fibromyalgia and related conditions
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001255655A1 (en) Treatment analysis systems and methods
IL146426A0 (en) Dual fpd and thin client
AU5311401A (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
EP1241577A3 (en) Methods and arrangements for improved parity-stripe processing
AU2002346504A1 (en) Therapeutic protein and treatments
AU2001292553A1 (en) Chronic illness treatment system and method
AU2002234773A1 (en) Pharmaceutically effective ginsenosides and their use
AU4445701A (en) Multiple human and mouse otoferlin isoforms
AU3895300A (en) Treatment of chronic fatigue syndrome
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU5522301A (en) Treatment of fibromyalgia and chronic fatigue syndrome
AU2002225881A1 (en) Treatment of chronic fatigue syndrome and fibromyalgia syndrome
AU2001271264A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
ZA200209632B (en) Methods for prevention of ulcers and improving physiological performance.
SI1274430T1 (en) Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU3663601A (en) Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
AU5374898A (en) The use of oxandrolone in the treatment of chronic fatigue syndrome
AU2001268762A1 (en) Treatment and therapy apparatus
AU2002310932A1 (en) The use of the protein uk114 for the treatment and the prevention of chronic active hepatitis
HK1053590A (en) Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)-desethyloxybutynin
AU2002318205A1 (en) Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
AU2002341745A1 (en) Nox reduction methods and apparatuses